{"nctId":"NCT00660504","briefTitle":"Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer","startDateStruct":{"date":"2008-04"},"conditions":["Lung Cancer"],"count":300,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Amrubicin Hydrochloride"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Etoposide-Cisplatin combined chemotherapy"]}],"interventions":[{"name":"Amrubicin Hydrochloride","otherNames":[]},{"name":"Etoposide-Cisplatin combined chemotherapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically/cytologically proven small cell lung cancer\n* Extensive disease\n* No prior chemotherapy regimen\n* Age 18 years or older\n* ECOG performance status of 0-1\n\nExclusion Criteria:\n\n* Brain metastasis requiring treatment\n* Treatment (Surgical or radiotherapy)of primary tumor\n* Interstitial pneumonia or pulmonary fibrosis\n* Abnormal cardiac function or myocardial infraction within 6 months before study enrollment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.79","spread":null},{"groupId":"OG001","value":"10.28","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Overall Survival at 6 and 12 Months","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.26","spread":null},{"groupId":"OG001","value":"86.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.59","spread":null},{"groupId":"OG001","value":"41.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.83","spread":null},{"groupId":"OG001","value":"5.72","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate","description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.80","spread":null},{"groupId":"OG001","value":"57.33","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":149},"commonTop":["Neutrophil count decreased","White blood cell count decreased","Nausea","vomit","Decreased appetite"]}}}